AR093908A1 - Fusion de la hormona de crecimiento humana y albumina, formulacion y usos de la misma - Google Patents
Fusion de la hormona de crecimiento humana y albumina, formulacion y usos de la mismaInfo
- Publication number
- AR093908A1 AR093908A1 ARP130104617A ARP130104617A AR093908A1 AR 093908 A1 AR093908 A1 AR 093908A1 AR P130104617 A ARP130104617 A AR P130104617A AR P130104617 A ARP130104617 A AR P130104617A AR 093908 A1 AR093908 A1 AR 093908A1
- Authority
- AR
- Argentina
- Prior art keywords
- human patient
- growth hormone
- human
- clinically effective
- fusion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000018997 Growth Hormone Human genes 0.000 title abstract 2
- 108010051696 Growth Hormone Proteins 0.000 title abstract 2
- 239000000122 growth hormone Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 238000009578 growth hormone therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
Abstract
Un método para tratar un paciente humano que necesita una terapia con la hormona de crecimiento que comprende administrar periódicamente a dicho paciente humano por más de dos semanas una cantidad eficaz de una composición que comprende un vehículo farmacéuticamente aceptable y una proteína de fusión cuya secuencia de aminoácidos se muestra en la SEQ ID Nº 1, para así tratar al paciente humano mediante una terapia. La presente también provee un método de tratamiento de un paciente humano que necesita de una terapia con la hormona de crecimiento que comprende administrar a dicho paciente humano, en un régimen clínicamente eficaz, una dosis clínicamente eficaz de una composición que comprende un vehículo farmacéuticamente aceptable y una proteína de fusión cuya secuencia de aminoácidos se muestra en la SEQ ID Nº 1, en donde la dosis clínicamente eficaz y el régimen clínicamente eficaz se seleccionan mediante una serie de pasos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261736267P | 2012-12-12 | 2012-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093908A1 true AR093908A1 (es) | 2015-06-24 |
Family
ID=50881605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104617A AR093908A1 (es) | 2012-12-12 | 2013-12-10 | Fusion de la hormona de crecimiento humana y albumina, formulacion y usos de la misma |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140162954A1 (es) |
| EP (1) | EP2931298A4 (es) |
| JP (1) | JP2016508125A (es) |
| KR (1) | KR20150106887A (es) |
| AR (1) | AR093908A1 (es) |
| AU (1) | AU2013359550A1 (es) |
| CA (1) | CA2892626A1 (es) |
| EA (1) | EA201591108A1 (es) |
| HK (1) | HK1216007A1 (es) |
| IL (1) | IL238897A0 (es) |
| MX (1) | MX2015007402A (es) |
| WO (1) | WO2014093354A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1217670A1 (zh) | 2013-01-15 | 2017-01-20 | Teva Pharmaceutical Industries Ltd. | Albu-bche调配物、其制造方法和用途 |
| WO2016011281A1 (en) * | 2014-07-17 | 2016-01-21 | Teva Pharmaceutical Industries Ltd. | FORMULATIONS OF AN ALBUMIN-hGH FUSION PROTEIN |
| WO2017136583A1 (en) * | 2016-02-02 | 2017-08-10 | Versartis, Inc. | Growth hormone treatment adherence system |
| JOP20190019A1 (ar) * | 2016-08-30 | 2019-02-12 | Genexine Inc | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) |
| ES2970423T3 (es) | 2017-08-24 | 2024-05-28 | Genzyme Corp | Esfingomielinasa ácida humana recombinante para su uso en el tratamiento de afecciones óseas anormales en pacientes con deficiencia de esfingomielinasa ácida |
| CN114240934B (zh) * | 2022-02-21 | 2022-05-10 | 深圳大学 | 一种基于肢端肥大症的图像数据分析方法及系统 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020156019A1 (en) * | 2001-04-20 | 2002-10-24 | Renasci, Inc., D/B/A Renasci Anti-Aging Center | Method of optimizing growth hormone replacement |
| US20020155990A1 (en) * | 2001-04-20 | 2002-10-24 | Renasci, Inc., D/B/A Renasci Anti-Aging Center | Method of optimizing growth hormone replacement |
| ES2425738T3 (es) * | 2001-12-21 | 2013-10-17 | Human Genome Sciences, Inc. | Proteínas de fusión de la albúmina |
| US20080167238A1 (en) * | 2001-12-21 | 2008-07-10 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| CA2577017A1 (en) * | 2004-08-30 | 2006-03-09 | Tercica, Inc. | Method and device for diagnosing and treating insulin-like growth factor deficiency disorders |
| AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
-
2013
- 2013-12-10 AR ARP130104617A patent/AR093908A1/es unknown
- 2013-12-10 MX MX2015007402A patent/MX2015007402A/es unknown
- 2013-12-10 KR KR1020157018674A patent/KR20150106887A/ko not_active Withdrawn
- 2013-12-10 EP EP13861675.0A patent/EP2931298A4/en not_active Withdrawn
- 2013-12-10 JP JP2015547472A patent/JP2016508125A/ja not_active Ceased
- 2013-12-10 EA EA201591108A patent/EA201591108A1/ru unknown
- 2013-12-10 AU AU2013359550A patent/AU2013359550A1/en not_active Abandoned
- 2013-12-10 WO PCT/US2013/074145 patent/WO2014093354A1/en not_active Ceased
- 2013-12-10 CA CA2892626A patent/CA2892626A1/en not_active Abandoned
- 2013-12-10 US US14/101,632 patent/US20140162954A1/en not_active Abandoned
- 2013-12-10 HK HK16103946.1A patent/HK1216007A1/zh unknown
-
2015
- 2015-05-19 IL IL238897A patent/IL238897A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2931298A4 (en) | 2016-07-06 |
| JP2016508125A (ja) | 2016-03-17 |
| IL238897A0 (en) | 2015-07-30 |
| AU2013359550A1 (en) | 2015-07-23 |
| KR20150106887A (ko) | 2015-09-22 |
| CA2892626A1 (en) | 2014-06-19 |
| HK1216007A1 (zh) | 2016-10-07 |
| MX2015007402A (es) | 2015-09-23 |
| WO2014093354A1 (en) | 2014-06-19 |
| EP2931298A1 (en) | 2015-10-21 |
| EA201591108A1 (ru) | 2015-11-30 |
| US20140162954A1 (en) | 2014-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124482A2 (es) | Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9 | |
| AR093908A1 (es) | Fusion de la hormona de crecimiento humana y albumina, formulacion y usos de la misma | |
| AR084939A1 (es) | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9, formas de dosificacion unitarias, articulo manufacturado, metodo | |
| MX2019012884A (es) | Terapia de combinacion. | |
| MX2019012113A (es) | Terapia génica para la deficiencia de la aadc. | |
| BR112014030404A2 (pt) | proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento | |
| NZ625391A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| MX2014000555A (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
| BR112015006828A8 (pt) | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1 | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| MX2019007779A (es) | Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe). | |
| NZ744233A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| AR112166A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de hepatitis b | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| EA201592040A1 (ru) | Иммуногенная композиция для применения в терапии | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| JOP20190019A1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
| RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
| BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
| JP2013520447A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |